Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
A panel of the Ministry of Health, Labor and Welfare (MHLW) on May 22 agreed not to cover males for HPV vaccinations under the national immunization program (NIP) for now due to their poor cost-effectiveness and the unavailability of a…
To read the full story
Related Article
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- LDP Lawmakers Seek Early Male NIP Coverage for HPV Jabs
June 18, 2025
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
- Lawmakers Request 4-Valent HPV Vaccination Program for Males to Minister
November 30, 2023
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
REGULATORY
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
- MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…